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Abstract 
Background: The objective of this study was to describe the profile and alcoholic status of a population with alcohol 
use disorders (AUD) requesting help from a psychiatric hospital to stop drinking, as well as their clinical outcome and 
care consumption over the 2 years following the request.
Methods: The visits were conducted at baseline (M0) and at 6, 12, 18 and 24 months (M6, M12, M18, M24). Demo‑
graphic, clinical and psychometric data [Beck Depression Inventory (BDI), AUDIT questionnaire, Global Assessment of 
Functioning (GAF) scale], and information regarding the use of psychiatric care and therapeutics were collected.
Results: The 330 subjects included were mostly male, aged 45.2 ± 10.2 years with an employment rate of 55.4 %, liv‑
ing alone (69.1 %), with a psychiatric comorbidity (60.9 %), especially depressive, and with few somatic complications. 
Their global functioning was poor (GAF score 49.14 ± 15.6), and less than 10 % were addicted to another substance. 
The abstinence rate at 24 months was 41.4 %, but only 23 % (20) abstained continuously between M0 and M24, and 
66.7 % (58) intermittently. The likelihood of abstinence at M24 was greater for females aged over 60 years. The BDI 
score decreased significantly between M0 and M24. In all, 56.2 % of the participants were re‑hospitalized after wean‑
ing, but were not integrated in long‑term medical care.
Conclusions: Abstinence after alcohol withdrawal fluctuated over time indicating the need for long‑term support. 
The treatment of AUD should not target total, continuous abstinence. Prognostic profiles combining socio‑demo‑
graphic, clinical and biological indicators must be established.
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Background
Over the past few centuries, the French society has 
treated alcoholism as an affliction in a complex context 
combining an ancestral way of life with divergent eco-
nomic, social, political and health interests. Alcohol use 
disorder (AUD) is a major direct and indirect cause of 
high rates of mortality and morbidity worldwide [1].
The lifetime prevalence of AUD is estimated to be 
between 7 and 12.5 % in most Western countries [2, 3]. 
In primary health care (general practice) in France, the 
prevalence of problematic alcohol use is estimated to be 
between 5.2 and 7.9 %, but may reach 11 % for risky or 
dangerous alcohol consumption [4, 5].
Long-term mortality in alcohol-dependent subjects is 
three to five times higher than the theoretical mortality 
calculated for non-alcohol-dependent subjects, and in-
hospital mortality caused by health problems linked to 
alcohol abuse is about 20  % in subjects hospitalized for 
psychiatric disorders or other diseases [5–9]. The social 
costs of AUD are high in France and throughout Europe, 
due to accidents, absenteeism, direct and indirect medi-
cal costs and negative impact on the family environment 
and the living conditions [10–12].
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Comorbidity with psychiatric problems is associated 
with a poorer prognosis of both conditions due to diag-
nostic problems and difficulties with the care pathway 
[13–15].
According to the World Health Organization (WHO), 
comorbidity is defined in psychiatry as “the occurrence, 
in a given person, of both a problem due to the consump-
tion of a psychoactive substance and another psychiat-
ric problem”. Comorbidity, or dual diagnosis, is a major 
public health issue for several reasons. The addition of an 
addictive comorbidity to a psychiatric problem increases 
the impact of the disease on the patient and their family 
[16], worsens violent behavior and breakups due to men-
tal problem [17] and increases the financial cost of the 
disease [16, 18]. The health benefits of weaning patients 
off alcohol are recognized, but the prognosis after with-
drawal of alcohol-dependent subjects with comorbid psy-
chiatric conditions is less well understood. In particular, 
we know little about the abstinence profile during the 
months following the cessation of alcohol consumption, 
or the links between fluctuations in alcohol consumption 
during this period and clinical data and biological factors. 
To improve our understanding of AUD in psychiatry, we 
carried out a cohort study, in a French psychiatric hospi-
tal, on 330 alcohol-dependent subjects requesting assis-
tance to stop drinking.
The aim was to establish a profile of the people con-
cerned (those with a high probability of a dual diagnosis 
of AUD and a comorbid psychiatric condition) and to 
describe the changes in their alcohol use status over the 
2  years following their withdrawal according to clinical 
and biological criteria, as well as their use of health-care 
services.
Methods
This study was carried out at Esquirol Hospital in Limo-
ges, France, a regional public psychiatric hospital with 
985 beds and the capacity to accommodate partially or 
fully hospitalized patients suffering from psychiatric 
problems and/or addiction. The frequency of AUD in 
the region and the consultation rates in centers special-
izing in alcohol-related problems (2.8 inhabitants aged 
between 20 and 70  years per thousand) were similar to 
those for the rest of France [19].
Study population
We included 330 people aged 18 years or over, present-
ing with AUD with dependence and requesting treatment 
to stop drinking during the first week of hospitalization 
in the hospital care units between September 2006 and 
September 2008. These individuals were included regard-
less of their mode of alcohol consumption and their 
psychiatric and/or somatic comorbid conditions. We did 
not include individuals with no fixed abode, presenting 
a progressive somatic condition with an estimated life 
expectancy shorter than 24  months, displaying notice-
able alterations of cognitive function preventing the 
evaluations (illiteracy, dementia or moderate to severe 
intellectual deficiency), as evaluated by the doctor in the 
care unit of hospitalization.
Ethics, consent and permissions
This study was carried out in accordance with French 
regulations governing biomedical research and was 
approved by the Research Board of the French Minis-
try of Health, the Limousin institutional review board 
[Comité de Protection des Personnes qui se prêtent à une 
Recherche Biomédicale (CPPRB)] and the French data 
protection agency (CNIL).
Each participant gave an informed written consent.
Study design
We avoided interventions that would affect the par-
ticipants’ outcome: 6-monthly follow-up visits with no 
major constraints for the participants were scheduled 
and integrated as closely as possible in the essential care 
procedures already established for this type of disease.
The investigators were not given any instruction about 
the type of therapeutics to use during the survey (either 
pharmacological or non-pharmacological), because of 
the semi-naturalistic nature of the study. So, the par-
ticipants received non-pharmaceutical support of their 
clinician, which consisted of a psychological/psychoso-
cial (BRENDA type) approach. Neither cognitive behav-
ioral therapy nor any other structured intervention was 
provided. The participants were thus re-evaluated every 
6 months, over a period of 2 years (M0, M6, M12, M18, 
M24), when hospitalized or as outpatients. The various 
visits were carried out during a medical consultation 
within the framework of the standard alcohol withdrawal 
follow-up program. If no medical visit was scheduled 
for one of the time points, a research nurse contacted 
the participant by telephone or e-mail to schedule an 
appointment for a clinical evaluation and to collect the 
biological samples required for the study. The reasons for 
follow-up visits not taking place were classified as “lost 
to follow-up”, “refusal” or “death”. Participants were con-
sidered “lost to follow-up” if they could not be contacted, 
if they did not respond when contacted, or if they were 
unable to attend (e.g., unable to travel, moved home, ill-
ness). Additional efforts were made to contact partici-
pants for the final follow-up visit at 24  months (letters, 
telephone calls, contact made with relatives or family 
doctor).
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Clinical, psychometric and biological measurements
At inclusion, a clinical evaluation was carried out by 
the doctor of the unit in which the patient was hospi-
talized (the consultant doctor). The principal diagnosis 
and comorbid conditions were identified according to 
the DSM-IV-TR criteria by the same consultant doctor, 
together with socio-demographic data (lifestyle, marital 
status, professional activity, source of income, protective 
measures), history of psychiatric care (number of years, 
number of hospitalizations), psychometric data [Alcohol 
Use Disorders Identification Test (AUDIT), Beck Depres-
sion Inventory (BDI), Global Assessment of Functioning 
(GAF) scale] and current treatment. A blood sample was 
taken as part of routine care by the unit staff. The com-
plete biological evaluation included measurements of 
mean corpuscular volume (MCV) and gamma-glutamyl 
transferase (γGT) activity at all follow-up visits, as well 
as determination of liver transaminase serum glutamate 
oxaloacetate transaminase (SGOT) and serum glutamic 
pyruvic transaminase (SGPT) activity at M0 and M24.
The data collected at the M6, M12, M18 and M24 fol-
low-up visits were, with the exception of the psychiatric 
care history already recorded, almost identical to those 
collected at inclusion. The following information dur-
ing the follow-up visits was collected: alcohol consump-
tion status, GAF score and comorbidities if the patient 
saw the doctor in the frame of their usual medical care 
pathway. AUDIT score (at M12 and M24), duration of 
care received (number of days of partial or full hospitali-
zation), outpatient follow-up (e.g., outpatient care, home 
visits by nurses), rate of rehospitalization after alcohol 
withdrawal between M0 and M24, time between thera-
peutic alcohol withdrawal and first care intervention 
were non-medical data collected by a research nurse or 
care staff nurses.
The AUDIT questionnaire [20] addresses current alco-
hol-related problems and explores behavior over the pre-
vious 12 months. Based on the total score, it is possible 
to classify alcohol consumers according to their type of 
consumption: risky consumption or use (score strictly 
below 7 in men, or 8 in women), misuse or harmful use 
(score between 7 and 12 in men, or between 8 and 11 
in women) or alcohol dependence (score strictly greater 
than 12 in men, or 11 in women).
The 13-item Beck Depression Inventory, or BDI, was 
used to evaluate depressiveness [21–23]. It yields a score 
from 0 to 39, which is interpreted as follows: 0–3: no 
depression; 4–7: mild depression; 8–15: medium to mod-
erate depression; 16 and over: severe depression.
Using the Global Assessment of Functioning (GAF) 
scale (DSM-IV-TR axis V), clinicians can evaluate the 
psychological, social and professional functioning of the 
patient on a hypothetical continuum from full mental 
health (100 or optimal functioning) to disease (0 or com-
pletely non-functional). The evaluator should not take 
into account changes in functioning due to limiting phys-
ical or environmental factors.
Abstinence was determined at M6, M12, M18 and 
M24 using a combination of clinical and biological cri-
teria: declaration of absence of alcohol consumption by 
the participant (interview with a doctor or a study nurse) 
and concordance between a mean corpuscular volume 
(MCV) below 96 µm3 and serum γGT activity at least half 
that at the time of alcohol withdrawal or below the refer-
ence value (<52 IU/ml for men or <32 IU/ml for women, 
according to analytical laboratory standards). Subjects 
not satisfying these criteria were considered non-absti-
nent. Relapse at one of the follow-up visits was deter-
mined by objective detection by the investigator, using 
clinical or biological means of “non-abstinence” after a 
period of abstinence. Abstinent subjects were those for 
whom abstinence was clearly established at each of the 
follow-up visits over the 24-month period. Intermittently 
abstinent subjects at M24 were defined as subjects for 
whom alcohol consumption was detected during at least 
one of the follow-up visits, but with abstinence at M24.
To determine the care pathway, the number of days 
of partial or full hospitalization was extracted from the 
computerized patient data records, which included medi-
cal and paramedical interventions, the number of days 
in hospital for each individual seen at the hospital and, 
depending on the information provided by the partici-
pants, admissions to other psychiatric or non-psychiatric 
facilities. The cumulative duration of these sequences was 
calculated in days for the 24-month follow-up period. 
Outpatient interventions were also recorded.
Statistical analysis
The results are presented as means ± standard deviations 
for continuous quantitative variables (age, BDI score, 
AUDIT score, GAF score, γGT levels, MCV, SGOT and 
SGPT levels, number of care interventions, duration of 
care sequences, etc.) and as percentages and absolute 
numbers for qualitative variables (sex, abstinence status, 
lifestyle, social welfare benefits, type of diagnosis, pres-
ence of comorbid conditions, socio-demographic data). 
The nonparametric Kruskall–Wallis test (or the Mann–
Whitney test for pairwise comparisons) was used to com-
pare the distributions of quantitative variables between 
groups, as these variables were not normally distributed. 
Differences in data between M0 and the other follow-up 
visits were compared using nonparametric paired Wil-
coxon tests.
Student’s t test was used to compare quantitative 
variables (mean scores on the Beck and AUDIT scales) 
between subgroups, because these variables followed a 
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normal distribution. Pearson’s χ2 test was used to com-
pare qualitative variables between subgroups, or Fish-
er’s exact test if the number of values in each cell was 
too small. We used Systat version 11 for Windows and 
p < 0.05 was considered to be significant.
We carried out a logistic regression analysis to identify 
the variables associated with abstinence, with the aim of 
determining the reasons for alcohol abuse. We carried 
out an initial series of univariate logistic regression anal-
yses. The variables considered in the univariate analysis 
were diagnostic category at M0, type of care (outpatient, 
hospitalization), age group (<30, 30–60, >60  years), sex 
(male/female), living alone (yes, no) and on social welfare 
benefits (yes/no). The variables with a p value less than 
0.2 in the univariate analysis were included in a multivar-
iate logistic model. Qualitative variables were integrated 
in the model without modification. Prior checks were 
carried out for the quantitative variables: if the odds ratio 
was demonstrated to be log-linear, then these variables 
were included in the model without modification; other-
wise, they were categorized by quartile. The initial mul-
tivariate model was simplified by a stepwise backward 
elimination method, such that the final model included 
only variables significantly associated with the variable to 
be explained. We checked that no confounding occurred 
during the stepwise elimination procedure. Following the 
univariate analysis on the study population of 246 people, 
the five variables retained for the multivariate analysis 
were care category, age group, sex, living alone (yes, no) 
and on social welfare benefits category. This part of the 
analysis was carried out using SAS software (SAS V9.3, 
SAS Institute, Cary, NC).
Results
General description of the cohort at inclusion
Socio-demographic, clinical and biological data for the 
participants at inclusion are summarized in Table 1.
The study population consisted largely of young men, 
mostly living alone (69.1 %). About one-third of the par-
ticipants declared living with someone else as a couple. 
Just over half the participants were employed, and most 
of their income came from private sources rather than 
from benefits.
In terms of addictive comorbid conditions, smok-
ing was highly prevalent. In contrast, few subjects were 
dependent on another psychoactive substance: 2.5  % 
were dependent on cannabis, 0.8 % on opiates and 0.4 % 
on cocaine.
In terms of psychiatric comorbid conditions, depres-
sion was the most frequent comorbid condition 
(p < 0.001), followed by psychotic and anxious disorders.
According to the AUDIT scores, seven had a score of 
7 or below. Clinical examinations confirmed alcohol 
Table 1 Characteristics of the population at inclusion
AUDIT alcohol use disorder identification test, BDI Beck Depression Inventory, 
GGT gamma-glutamyl transferase, MCV mean corpuscular volume, SGOT 
serum glutamate oxaloacetate tranasminase, SGPT serum glutamic pyruvic 
transaminase
N = 330, unless otherwise indicated Mean ± SD (n) or  % (n)
Age (years) 45.2 ± 10.2
Sex‑ratio (male/female) 3.6 (258/72)
Single/divorced/widowed (324) 69.1 % (224)
Lifestyle (324)
 Couple 31.5 % (102)
 Living alone 39.1 % (127)
 Other (family, friends…) 29.4 % (97)
With a professional activity 55.4 % (174)
Resources (327)
 Own or from family 67.9 (222)
 Social 32.1 (105)
Smokers 80.2 % (186)
With psychiatric co‑morbidity 60.9 % (200)
Type of psychiatric comorbidity
 None 39.1 % (129)
 Dementia 1.5 % (5)
 Psychosis 4.6 % (15)
 Mood and affective disorder 30.6 % (101)
 Anxiety disorder 5.5 % (18)
 Personality disorder 26.1 % (87)
With somatic comorbidity 7.6 % (25)
Global Assessment of Functioning 49.14 ± 15.60
AUDIT (312) 26.9 ± 7.7
 Risk use (score ≤7) 2.2 (7)
 Harmful use (7< score <13) 2.2 (7)
 Dependence (score ≥13) 95.5 (298)
BDI score (308) 13.5 ± 7.1
BDI categories
 Absent 5.8 (18)
 Slight 16.2 (50)
 Moderate 41.6 (128)
 Severe 36.4 (112)
MCV (µm3) 97.9 ± 6.2
 % >normal values (n) 55.9 (181)
SGOT (UI/L) 47.4 ± 53.5
 % >normal values (n) 39.3 (129)
SGPT (UI/L) 42.5 ± 41.5
 % >normal values (n) 41.5 (136)
GGT (UI/L) (mean ± SD) 222.7 ± 408.2
 % >normal values (n) 61.6 (202)
Current psychotropic treatment
 Neuroleptics 14.2 % (47)
 Atypical antipsychotics 14.5 % (48)
 Thymoregulators 7.8 % (26)
 Antidepressants 52.7 % (174)
 Anxiolytics 90 (297)
 Benzodiazepines 88.4 % (292)
 Related to benzodiazepines 23.0 % (76)
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dependence in these 14 cases. Mean daily consumption 
(TAC) was high, 34.6 % (108 people) of the participants 
declared consuming at least 10 units per day and 51.6 % 
(161 people) 5–8 units per day. Similarly, the number of 
heavy drinking days corresponded to “almost every day” 
for 51 % of the participants (159 people). The mean BDI 
score indicated moderate to severe depressiveness for 
this population, with a total proportion of 78 % of those 
included presenting a high score for depression.
Only a few somatic comorbid conditions were reported: 
ankylosing spondylitis (3 cases), esophagus, stomach and 
duodenum diseases (4), respiratory diseases (5), liver dis-
ease (1), viral infections (3), heart disease (3), metabolic 
disorders (2), epilepsy (2), breast cancer (1) and other 
physically disabling conditions (4 cases).
The values for biological markers of liver function and 
alcohol dependence (γGT and MCV) were both above 
the normal range (reference values) for 42 % of the par-
ticipants (136 people). The values for these two markers 
were in the normal range for 24.7  % of the participants 
(80 people).
Regarding drug therapy, the most frequently prescribed 
drug at inclusion was benzodiazepine, followed by anti-
depressants, which were taken by more than half the 
participants.
Changes over the 24 months following the request for help 
to stop drinking and abstinence
Data were collected for about half the patients at the M6, 
M12 and M18 visits (Table 2).
However, data were obtained for a larger proportion 
of the patients at M24, presumably due to the greater 
effort made to contact participants and, if the partici-
pants themselves could not be contacted, their families. 
The availability of biological data, and thus knowledge 
about abstinence, was more limited as it was restricted to 
patients we were able to trace.
The differences between the population at inclusion 
and the population at M24 correspond to the difference 
in the proportion of subjects living alone (35.2 % at M0 
and 37.7 % at M24, p < 0.001), being single/widowed or 
divorced (34.5 % at M0 versus 31.3 % at M24; p < 0.001), 
having a professional activity (57.6  % at M0 and 41.2  % 
at M24, p  <  0.001) and being on benefits (71.4  % at 
M0 versus 60.1  % at M24, p  <  0.001). Neither age 
(45.2 ± 10.2 years versus 45.6 ± 10.2 years, p = 0.12) nor 
sex (78.7 % men at M24 versus 78.2 % at M0, p = 0.681) 
differed between M0 and M24.
A large number of subjects (21) died during the 
24 months of the study.
Overall, the abstinent individuals did not follow a 
linear trajectory between M0 and M24. Data for all 
the follow-up visits were available for 87 people, 58 of 
whom (66.7 %) displayed intermittent abstinence. Only 
23  % (20 participants) were entirely abstinent during 
the entire period from M0 to M24. Clinical data, but 
without biological data, were obtained for 281 partici-
pants; 24.6 % (69 participants) declared a total absence 
of alcohol consumption over the entire 24-month fol-
low-up, whereas 61.5  % reported intermittent alcohol 
consumption.
The number of subjects remaining abstinent varied 
according to the criteria: clinical or biological. An analy-
sis of the coherence of the two definitions of abstinence 
yielded a kappa value of 0.2307, with a 95 % confidence 
interval of 0.08–0.38. These values indicate poor con-
cordance between the two measures.
We considered all records of diagnoses of comorbid 
conditions at any time point during the care of the sub-
ject within the 24 months following alcohol withdrawal. 
Mood disorders were the most frequently reported. 
The type and nature of the psychiatric co-morbidities 
reported at M24 differed from those at M0 (p  <  0.001) 
with significantly less subjects with mood disorders or 
anxiety disorders, but an equivalent proportion of psy-
chotic disorders, suggesting that this category benefits 
from better insertion in the care system.
Few somatic comorbid conditions were reported dur-
ing the follow-up. At the various follow-up visits, we 
recorded all diagnoses for diverse conditions requiring 
treatment and causing some disability (e.g., lower back 
pain) (n  =  5), episodic conditions (2), viral infections 
including hepatitis (9), lung and ear diseases (2), meta-
bolic problems (obesity) (1) and cirrhosis (1). The pro-
portion of somatic conditions reported between M0 and 
M24 did not differ (p = 0.516).
The mean scores for the psychometric scales indicated 
an improvement in the general state of the participants 
from M6 onward. At each follow-up visit, we observed 
an improvement in GAF score (p  <  0.01), a significant 
decrease in depression score (p < 0.001) and a significant 
decrease in alcohol dependence (AUDIT score; p < 0.001) 
with respect to the values obtained at M0. The values 
obtained at the various follow-up visits (M6, M12, M18 
and M24) did not differ for the population as a whole. In 
addition, the mean values of the biological markers used 
(γGT and MCV) returned to normal during the follow-
up, whereas they were outside this range at M0.
Before requesting assistance to stop drinking, the par-
ticipants had been hospitalized more than four times 
on average (Table 3). Only 39 % (129 participants) were 
admitted to a psychiatric unit for the first time when they 
requested assistance to stop drinking. Similarly, the mean 
duration of psychiatric care before the request for assis-
tance was relatively short, although 19 % of the patients 
had been receiving care for over 10 years.
Page 6 of 11Nubukpo et al. Ann Gen Psychiatry  (2016) 15:22 
Table 2 Quantitative and qualitative variables collected at 6 (M6), 12 (M12), 18 (M18) and 24 (M24) months after alcohol 
withdrawal
AUDIT Alcohol Use Disorder Identification Test, BDI Beck Depression Inventory, GGT gamma-glutamyl transferase, MCV mean corpuscular volume, SGOT serum 
glutamate oxaloacetate transaminase, SGPT serum glutamic pyruvic transaminase
M6 M12 M18 M24
Mean ± SD or  % N Mean ± SD or  % N Mean ± SD or  % N Mean ± SD or  % N
With any data 51.8 171 38.6 146 42.7 141 51.8 249
With data to assess abstinence 27.6 91 33.9 112 33.9 112 75.5 171
Abstinent 57.1 52 40.2 45 46.4 52 41.4 103
Reasons for the absence of follow‑up
 No data—lost 47.8 76 62.4 118 38.8 128 13.3 13
 Impossible to come 24.8 82 34.4 65 15.2 50 19.4 64
 Death 0.03 1 3.2 6 7.3 14 21.4 21
With a psychiatric comorbidity 56.7 97 63.7 93 42.5 77 48.2 120
Type of psychiatric comorbidity 37.7
 None 29.9 29 42.0 39 5.19 29 46.7 50
 Dementia 0 0 0 0 15.5 4 0 0
 Psychosis 9.3 9 18.2 17 20.7 12 14.9 16
 Mood disorder 37.1 36 20.4 19 3.9 16 13.1 14
 Anxiety disorder 9.3 9 3.2 3 24.7 3 1.9 2
 Personality disorder 21 18 20.4 19 19 15.9 17
With somatic comorbidity 11.3 11 6.5 6 5.2 4 5.6 6
Global Assessment of Functioning 59.9 ± 19.7 70 56.7 ± 20.1 66 59.7 ± 20.6 63 58.2 ± 19.3 88
AUDIT score – 14.5 ± 12.2 130 – 14.0 ± 12.1 162
 Risk use (score ≤7) – 36.2 45 – 40.1 65
 Harmful use (7 < score <13) – 13.1 17 – 6.2 10
 Dependence (score ≥13) – 50.8 66 – 50.6 82
BDI 8.3 ± 7.3 163 7.8 ± 7.5 133 7.2 ± 7.1 130 7.7 ± 7.3 168
 Absent 29.5 48 39.1 52 36.9 48 40.2 68
 Slight 25.8 42 15.8 21 24.6 32 20.1 34
 Moderate 28.8 47 30.1 40 25.4 33 21.3 36
 Severe 15.9 26 15.0 20 13.1 17 18.3 31
MCV (UI/L) 94.9 ± 6.0 175 95.4 ± 5.9 140 94.4 ± 5.9 141 94.3 ± 6.2 169
 % >normal values (n) 34.9 61 40 56 30.5 43 34.3 58
TGO (UI/L) – – – 39.0 ± 55.3
 % >normal values (n) 24.6 41
TGP (UI/L) – – – 38.8 ± 61.9
 % >normal values (n) 29.9 50
GGT (UI/L) 94.9 ± 6.0 175 108.0 ± 269.3 143 112.9 ± 290.8 140 156.0 ± 379.9 168
 % >normal values (n) 43.4 76 40.6 58 41.4 58 18.8 82
Current psychotropic treatment
 Neuroleptics 15.3 27 13.3 20 18.0 27 15.0 36
 Atypical antipsychotics 25.0 44 24.6 37 24.0 36 23.0 55
 Thymoregulators 13.6 24 12.0 18 12.0 18 11.3 27
 Antidepressants 63.0) 111 65.3 98 62.6 94 51.8 124
 Anxiolytics 67.0 118 65.3 98 61.3 92 57.3 137
 Benzodiazepines 56.2 99 56.0 84 11.5 38 48.9 116
 Related to benzodiazepines 22.1 39 17.3 26 25.1 83 18.1 43
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Almost half the participants were readmitted in the 
24 months following withdrawal, whereas a quarter only 
had outpatient follow-up (23.6  %). Patients returned to 
the care system relatively rapidly, with rehospitalization 
or the first care intervention within the first 6  months 
after weaning off alcohol. A total absence of care in the 
24  months after weaning off alcohol was observed for 
only 7 % of the participants (Table 3).
We further studied the psychiatric comorbid condi-
tions and characteristics according to care data. Patients 
with psychiatric comorbid conditions attended more 
follow-up visits for this study than patients without such 
comorbid conditions. For example, 51.4  % (90 partici-
pants) of subjects with comorbid conditions attended at 
least three follow-up visits, in comparison with only 
32.3  % (50 participants) of those without comorbid 
conditions (p  =  0.011). The first care intervention was 
between M0 and M6 for 70.9 % (124 participants) of sub-
jects with comorbid conditions, but only 62.6 % without 
comorbid conditions (p < 0.001). A total absence of treat-
ment was observed for only 13.1  % (23 participants) of 
subjects with comorbid conditions and 25.8  % (40 par-
ticipants) with no psychiatric comorbid condition.
We looked for an association between socio-demo-
graphic variables (age, sex, source of income, living alone) 
or care received during the 24-month follow-up (hospital-
izations, outpatient care) with abstinence status at M24.
Following the univariate analysis of the study popu-
lation, the five variables retained for the multivariate 
logistic regression were care category (p  =  0.199), age 
(p = 0.015), sex (p = 0.033), living alone (p = 0.146) and 
private income (p = 0.118).
In the multivariate logistic model, age and sex were 
significantly associated with abstinence at 24 months, as 
older age was associated with a higher likelihood of absti-
nence at 24 months. Participants aged over 60 years were 
therefore six times more likely to be abstinent at the end 
of the 24-month follow-up than participants under the 
age of 30  years. Women were twice as likely as men to 
be abstinent after the 24-month follow-up (Table  4). At 
the end of the manual stepwise descending procedure 




The study population was mostly male (78  % men) and 
was therefore comparable to the populations in epide-
miological studies carried out in the USA: the National 
Comorbidity Survey [24, 25] and the National Epide-
miologic Survey on Alcohol and Related Conditions 
(NESARC cohort study) [26]. Marital status (69  % were 
single, divorced or widowed) differed significantly from 
that of the general population in the region (32.5 % sin-
gle, 7  % divorced, 10.5  % widowed, corresponding to 
50  %) [27]. Insertion in the workplace was better than 
expected for individuals requesting care in a psychiatric 
unit, because psychiatric problems are known to be a 
factor favoring employment loss and a low likelihood of 
returning to work [28]. However, the cohort employment 
rate (55.4 %) was lower than that of the general popula-
tion in Limousin (70 % of 15- to 49-year-olds and 51 % of 
50- to 64-year-olds work) [29] or in France (65.1 % of the 
French population was in paid work in March 2008, and 
the current proportion is 64.1  %). The GAF score [30], 
which measures overall functioning, improved over the 
24-month follow-up.
The AUDIT score has a considerably valuable number 
of features for the routine diagnosis of risky or danger-
ous alcohol consumption. However, it is less relevant for 
follow-up as it was designed as a screening test [20]. Nev-
ertheless, at least three of the items, those concerning 
the frequency of alcohol consumption, total alcohol con-
sumption and the number of heavy drinking days (at least 
six units) decreased between M0 and M24 in our study, 
for subjects with high consumption levels at M0. This is 
particularly relevant as decreases of only a few units for 
“heavy drinkers” have been shown to have an exponential 
effect on damage reduction [31].
The mean BDI score for the cohort was high for a pop-
ulation not included on the basis of depressive illness. 
However, this scale only evaluates the intensity of symp-
toms associated with depression and has no diagnostic 
value.
Depressive mood is very frequent immediately after 
alcohol withdrawal, potentially due, at least in part, to 
the high frequency of depressive symptoms in this pop-
ulation. The decrease in BDI depression scores for all 
patients after 6  months of follow-up reflects the posi-
tive consequences of a decrease in alcohol consumption 
Table 3 Psychiatric care before  inclusion to  the study 
(before alcohol withdrawal) and  during the 24  months 
after alcohol withdrawal (between M0 and M24) (n = 330) 
[(mean ± SD or % (n)]
Before alcohol withdrawal
 Number of psychiatric hospitalizations 4.4 ± 8.3
 Duration of psychiatric care (years) 4.5 ± 7.1
Between M0 and M24
 Cumulative number of days of complete hospitalization 79.8 ± 130
 Cumulative number of days of psychiatric home care 52.4 ± 71.9
 Rehospitalization 56.2 % (164)
 Number of days between withdrawal and first psychi‑
atric care
146.4 ± 162.8
 Home visits 1.5 ± 8.4
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on depressive symptoms [5, 32]. More than half the par-
ticipants presented a dual diagnosis of AUD and another 
psychiatric problem. The frequency of psychiatric prob-
lems among alcohol-dependent patients in the general 
population has already been shown to be high [33–35] 
and is even higher in hospitalized populations [36]. This 
may reflect the greater demand for assistance to stop 
drinking by patients with comorbid conditions, otherwise 
known as Berkson’s bias [37, 38]. This effect was ampli-
fied in our study by the recruitment of participants from 
a psychiatric hospital environment. In our study popula-
tion, depression was the most frequent comorbid psychi-
atric condition, ahead of psychotic, anxious and bipolar 
disorders, both at inclusion and after 24  months. Some 
of the patients initially diagnosed as having depression 
in this cohort may actually have had bipolar depression, 
and this might result in a need to readjust the diagnoses 
during the follow-up period. Previous studies have high-
lighted the difficulties associated with these diagnoses in 
alcohol-dependent patients [39, 40].
Most studies have shown that depressive symptoms 
are frequent in people with AUD, but that characterized 
depressive episodes are rare. These transient symptoms 
of depression not fulfilling the criteria for diagnosis of a 
major depressive episode disappear after 1–2  weeks of 
abstinence [41, 42] and should not lead to treatment with 
an antidepressant unless they persist for much longer [15].
The high death rate of 6.4  % (21/330) among the 
patients seeking a cure for alcohol dependence during 
the survey can be emphasized. The absolute risk of dying 
from an adverse alcohol-related condition increases line-
arly with the amount of alcohol consumed over a lifetime 
[43]. The annual absolute risk of dying from an alcohol-
related disease for people aged over 15 years across the 
population in the World Health Organization (WHO) 
European Region is around 0.1 for a daily consump-
tion of over 70 g. In 2012, 5.9 % of all global deaths were 
attributable to alcohol, with the highest proportion in the 
WHO European Region [43].
Finally, we observed an increase in the prevalence of 
psychiatric problems during the course of the study, 
potentially corresponding to an initial underestimation 
of comorbid psychiatric conditions and the occurrence of 
new clinical episodes of psychiatric conditions during the 
2-year follow-up period [1, 24, 25]. The clinical subpop-
ulation with a dual diagnosis of AUD and a psychiatric 
problem should be studied in greater detail, because such 
dual diagnoses have been shown to be associated with a 
poorer prognosis for both conditions [14, 33, 34, 44].
Abstinence and changes during the 24 months 
following the request for assistance to stop drinking
Overall, 41.4  % of the subjects were still abstinent at 
24  months. However, focusing solely on abstinence at 
this last time point (M24) does not provide an entirely 
satisfactory evaluation of the success of the intervention. 
Our results also raise questions regarding the criteria 
used to evaluate abstinence. The use of a combination 
of clinical and biological criteria for abstinence makes 
it possible to optimize the detection of “false abstinent” 
individuals. However, in practice, these criteria may be 
too strict, potentially masking real differences. The use of 
abstinence as the only criterion for evaluating care in the 
treatment of patients with AUD is now seen as somewhat 
heavy handed. Decreasing consumption also seems to be 
a beneficial objective, with the aim of decreasing morbid-
ity and mortality [45–47]. Finally, old age (over the age 
of 60 years) and being female were the only criteria sig-
nificantly linked to successful weaning off alcohol after 
24 months in our study. However, this finding should be 
interpreted with caution given the small proportions of 
women and subjects over the age of 60 years in our study 
population. Nevertheless, these individuals may con-
stitute subgroups of the population with more difficult 
Table 4 Odds ratios (OR) unadjusted and  adjusted (logistic regression) for  the association of  age and  gender to  absti-
nence at 24 months after alcohol withdrawal
Effect Unadjusted Adjusted
Odds ratio 95 % confidence interval Odds ratio 95 % confidence interval
 Ambulatory care 0.93 0.36 2.42
Hospitalization 0.58 0.25 1.37
Age <60 2.10 0.66 6.66 2.10 0.66 6.66
Age >60 7.58 1.74 33.09 7.58 1.74 33.09
Gender female/male 1.98 1.06 3.70
Living alone 0.67 0.39 1.15
Own resources 1.59 0.89 2.84
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access to care for AUD and, thus, with probably a much 
greater motivation to succeed.
The request for help to stop drinking is part of a long, 
very personal process. It is invariably preceded by a long 
progressive phase that is not sufficient in itself to cre-
ate the conditions required for sustained abstinence. 
This process involves alternating periods of alcohol con-
sumption and partial or complete abstinence, sometimes 
linked to identifiable factors, but above all to conflicts 
and internal thought processes.
Sustaining medium- and long-term abstinence seems 
to be directly linked to the attention devoted to the 
addiction problem, the psychiatric conditions with 
which it is comorbid and the quantity and pertinence of 
care delivered [33, 48]. Patients with comorbid psychi-
atric conditions were more compliant in this study. This 
may have been due to their stronger demand for help or 
prior integration in a follow-up system, thereby facilitat-
ing follow-up for this study. This was the case, for exam-
ple, for patients with schizophrenia and AUD. For the 
patients, the follow-up was part of the care process. It 
has also been reported that patients with a dual diagnosis 
make greater use of care facilities [49], including emer-
gency services [16]. In the context of care rationaliza-
tion, changes in the use of care facilities over time should 
be considered in more detail. In contrast, few of the 
interventions by psychologists and social workers took 
place in the patients’ homes, presumably reflecting the 
largely institutional and medical management of AUD in 
France. The results provided here give an evidence of the 
patients—institution interaction, which does not appear 
to be so intensive and tightened.
Antidepressant use was high (52.7  %). In France, rec-
ommendations are to wait for 2–4  weeks after weaning 
off alcohol before introducing antidepressant treatment, 
unless the symptoms are acute and intense with a risk of 
suicidal behavior. Furthermore, benzodiazepines, which 
are authorized for use as anxiolytics for short periods of no 
longer than 12 weeks, should not be prescribed for longer 
than the standard duration of the weaning period, which is 
of the order of about 10 days at most [50]. It can be high-
lighted that the investigators were not given any instruc-
tions regarding the type of therapeutics to use during the 
survey (either pharmacological or non-pharmacological) 
because of the semi-naturalistic nature of the study,
Bias
The results obtained in this study were collected for a 
specific population: chronic alcohol consumers who had 
contacted the hospital’s psychiatric department. Overall, 
20.30 % of the patients were lost to follow-up at M24, but 
not all the patients attended all the follow-up visits. This 
limited the sample size, with deleterious consequences 
for the statistical analysis. Indeed, this study was semi-
naturalistic in design, with data collection based largely 
on the integration of participants in a care pathway that 
varied from patient to patient. Nevertheless, we con-
sider this one of the strengths of the cohort, as it includes 
strict evaluations linked to the study of a fate more com-
patible with a patient-focused care pathway for subjects 
requesting help from the psychiatric care system to stop 
drinking.
Conclusion
In this observational cohort study of 330 patients request-
ing assistance from the psychiatric care system to stop 
drinking, we found that only 25  % of the participants 
remained abstinent throughout the entire 24-month fol-
low-up, with 41.4  % of the participants considered absti-
nent after 2  years; 66.7  % of the participants displayed 
intermittent abstinence over the 2-year follow-up period. 
Some sub-groups may be defined with regard to their 
chance of abstinence and further characterization may be 
helpful in the routine practice. However, patients with a 
comorbid psychiatric condition underwent a larger num-
ber of follow-up visits for the study, together with a larger 
number of treatment sequences and health-care interven-
tions. The lack of agreement between clinical and biological 
data for abstinence and the other results obtained suggest 
that studies of combined markers or prognosis, biopsycho-
social outcome and fate after weaning are required. These 
findings also confirm the importance of not focusing solely 
on short-term management and abstinence.
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